•
PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of…
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022 financial report, demonstrating robust growth with revenues of RMB 37.715 billion (USD 5.5 billion), an increase of 9.12% year-on-year (YOY), and net profits of RMB 2.598 billion (USD 379.3 million), marking a 13.24% YOY increase.…
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first major step in expanding its presence in Latin America (LATAM) with the formal opening of its office in São Paulo, Brazil. This strategic move positions BeiGene to tap into the largest oncology market in the…
•
US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin’s founder Dr. Eugene Chen…
•
Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from the US FDA for its second-generation PARP inhibitor, mefuparib (CVL218). The designation is in recognition of the drug’s potential as a treatment for cholangiocarcinoma, a rare and aggressive form of cancer. Advantages of CVL218 Over…
•
New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David Radspinner and the securing of USD 64 million in funding led by Decheng Capital. The company, established by scientists Sun Junwei and Dr. Zhou Shangzhen, who were instrumental in the development of the first viral…
•
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB 200 million (USD 29 million). This funding is supported by a consortium of investors including Yangzhou Guojin Investment, Jiangsu Dingxin Capital, Yangzhou Longchuan Holdings, a leading international sovereign fund, Lilly Asia Ventures, Quan Capital, 3H…
•
Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (NYSE: ADCT), announced that the primary endpoint has been reached in a Phase II regulatory study. The study assessed the efficacy and safety of Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC)…
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication approval from the National Medical Products Administration (NMPA) for its Janus kinase (JAK) 1/2 inhibitor, Jakavi (ruxolitinib), as a treatment for patients with acute graft versus host disease (acute GVHD). This marks the first approval…
•
China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical Products Administration (NMPA) for its Nav1.8 inhibitor, HBW-004285, which is intended for the treatment of acute and chronic pain. Understanding the Role of Nav1.8 in Pain SignalingNav1.8 is a tetrodotoxin-insensitive voltage-gated sodium ion channel that…
•
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal radiofrequency denervation (RDN) system has successfully reached its primary clinical endpoint in the randomized, controlled Iberis-HTN study for the treatment of primary hypertension. Iberis-HTN Study ResultsThe prospective, multicenter, blinded, randomized controlled trial was designed to…
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study and two Phase III clinical studies for its APP13007, a modified hormone nano suspension eye drop, have successfully reached their clinical endpoints in the United States. The clinical results demonstrate that APP13007 exhibits significant efficacy…
•
Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence grouping Phase I clinical study for its factor Xl-targeted RNAi drug, STP122G. The US-based trial is designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy subjects initially, before expanding to its…
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to the National Medical Products Administration (NMPA) in China for its in-licensed daxibotulinumtoxin A for injection (RT002). The drug is intended for use in the temporary improvement of moderate to severe frown lines in adults, attributed…
•
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has declared that the Phase III FLAMES study for senaparib (JS109/IMP4297), a PARP inhibitor co-developed with Impact Therapeutics Inc., has achieved the pre-set optimal efficiency threshold, marking the trial’s primary endpoint. The study targets the first-line maintenance treatment for stage III/IV ovarian cancer,…
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has initiated the construction of a state-of-the-art biomacromolecules research and development (R&D) and manufacturing center in the Wai Gao Qiao Tax-Free Zone of Shanghai. This new facility aims to offer biopharmaceutical companies and new drug developers comprehensive one-stop CDMO services,…
•
Blueray Med, a leading high-end laser medicine device manufacturer based in Xi’an, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The round was led by Hefei Zhonghe Oupu Medical, with the Health Industry Fund Partnership and Shaanxi Investment Fund participating as leading investors. The…
•
Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of the programmed death-1 (PD-1) inhibitor, Anniko (penpulimab), in Australia, Singapore, and South-East Asia. The drug is developed by the joint venture (JV) CTTQ-Akeso (Shanghai) Biomed Tech Co., Ltd, a partnership between Akeso Inc. (HKG: 9926)…
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the appointment of Dr. Mythili Koneru as its new Chief Medical Officer (CMO). In this role, Dr. Koneru will be responsible for leading the company’s clinical development and medical affairs programs, further strengthening Legend’s executive team. Dr. Koneru’s Background and ExperienceDr. Koneru…
•
China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its biosimilar version of Roche’s Avastin (bevacizumab) has been accepted for review by Brazil’s National Health Surveillance Agency (ANVISA). Luye’s Biosimilar Approval and Global OutlookLuye’s biosimilar bevacizumab was approved in China in 2021 to treat indications…